Amelioration of hyperglycemia by regular injections of recombinant human EPO (rhEPO) has been described in rodents (31–33), but similar to previous studies about hypoxia conclusions were hampered by an unaccounted influence of weight differences and/or hematocrit-sensitive glucose meters. Here, EPO is linked to Hyperglycemia.